HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a Buy and lowers the price target from $18 to $15.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a Buy and lowers the price target from $18 to $15.